Physiological significance of pericoronary inflammation in epicardial functional stenosis and global coronary flow reserve

Yoshihisa Kanaji1, Tomoyo Sugiyama1, Masahiro Hoshino1, Toru Misawa1, Tatsuhiro Nagamine1, Yumi Yasui1, Kai Nogami1, Hiroki Ueno1, Hidenori Hirano1, Masahiro Hada1, Masao Yamaguchi1, Rikuta Hamaya1, Eisuke Usui1, Taishi Yonetsu2, Tetsuo Sasano2 & Tsunekazu Kakuta1,2

Both fractional flow reserve (FFR) and global coronary flow reserve (g-CFR) provide prognostic information in patients with stable coronary artery disease (CAD). Inflammation plays a vital role in impaired endothelial dysfunction and atherosclerotic progression, potentially predicting cardiovascular mortality. This study aimed to evaluate the physiological significance of pericoronary adipose tissue inflammation assessed by CT attenuation (PCATA) in epicardial functional stenosis severity and g-CFR in patients with CAD. A total of 131 CAD patients with a single de novo epicardial coronary stenosis who underwent coronary CT-angiography (CCTA), phase-contrast cine-magnetic resonance imaging (PC-CMR) and FFR measurement were studied. PCATA was assessed using the mean CT attenuation value. G-CFR was obtained by quantifying absolute coronary sinus flow (ml/min/g) by PC-CMR at rest and during maximum hyperemia. Median FFR, g-CFR, and PCATA values were 0.75, 2.59, and −71.3, respectively. Serum creatinine, NT-proBNP, left ventricular end-diastolic volume, and PCATA were independently associated with g-CFR. PCATA showed a significant incremental predictive efficacy for impaired g-CFR (< 2.0) when added to the clinical risk model. PCATA was significantly associated with g-CFR, independent of FFR. Our results suggest the pathophysiological mechanisms linking perivascular inflammation with g-CFR in CAD patients.
model, including FFR, remains unknown. Thus, in the present study, we tested the hypothesis that PCATA was significantly associated with both FFR and g-CFR. We further evaluated if PCATA showed the incremental discriminatory efficacy to predict impaired g-CFR when added to the prediction model including FFR. To test this hypothesis, the present study was undertaken by measuring FFR, g-CFR, and PCATA in CAD patients with a single epicardial de novo lesion and preserved systolic function.

**Methods**

In this retrospective study, we enrolled consecutive patients with a single de novo intermediate to severe stenosis (30–90% by visual estimation) by clinically indicated CCTA for suspected CAD and subsequently underwent PC-CMR examination prior to diagnostic coronary angiography (CAG) within 60 days at Tsuchiura Kyodo General Hospital (Fig. 1). A total of 1205 patients with low to intermediate risk of obstructive coronary artery disease underwent CCTA from January 2018 to December 2019. CCTA indication was in accordance with a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention\(^1\)\(^2\) and finally decided at the physician's discretion. Patients with an intermediate to severe de novo lesion (30–90% in diameter stenosis) in a single vessel on CCTA who gave the written informed consent were enrolled and underwent PC-CMR study for quantifying coronary sinus flow and g-CFR. Patients without stenosis more than 30% on CCTA, with severe stenosis (> 90%) or chronic total occlusion, significant stenosis in the left main trunk, and multiple obstructed vessels (> 30% in diameter stenosis) were excluded. In the remaining 150 patients, 136 patients with written consent underwent invasive coronary angiography and subsequent FFR measurements for the lesions. Inclusion criteria included the following: age > 20 years and the detection of an identifiable, de novo lesion located in the proximal or mid-portion of a native coronary artery. Stable coronary artery disease was defined by consistent frequency, duration, or intensity of anginal symptoms within the 6 weeks before CAG. Exclusion criteria included previous coronary artery bypass surgery or percutaneous coronary intervention (PCI), ongoing dialysis, renal insufficiency with a baseline serum creatinine level > 1.5 mg/dl, angiographically significant left main coronary artery disease, culprit lesion of the acute coronary syndrome, an occluded culprit lesion, multiple vessel disease, visible collateral flow and contraindication to CMR (e.g., pacemaker, internal defibrillator or other incompatible intracorporeal foreign bodies, pregnancy, and claustrophobia). Patients with impaired systolic ejection fractions (< 50%) were also excluded. The study protocol agreed with the Declaration of Helsinki and was approved by the institutional ethics committee of Tsuchiura Kyodo General Hospital. All patients provided written informed consent before enrollment in this study.

**Cardiac catheterization and physiological assessment.** Each patient initially underwent standard selective coronary angiography via the radial artery using a 5-F or 6-F catheter system. Coronary angiograms were analyzed quantitatively using a QAngio XA system (Medis Medical Imaging Systems, Leiden, The Netherlands). FFR was measured during stable hyperemia induced by intravenous adenosine (140 μg/kg/min through a central vein). These measurements were performed as part of the diagnostic catheterization, and the patients with FFR values ≤ 0.80 underwent ad-hoc PCI.
Coronary CT-angiography acquisition. CCTA was performed using a 320-slice CT scanner (Aquilion ONE; Canon Medical Systems Corporation, Otawara, Tochigi, Japan) in accordance with the society of cardiovascular computed tomography guidelines. Details are described in Method 1 in the Supplemental Materials.

Analysis of PCATA. In the present study, the crude analysis of PCATA of all three main coronary vessels was performed. The mean PCATA of three main coronary vessels was used for the analysis. PCATA analysis was performed in the proximal 40 mm segments of left anterior descending coronary artery and left circumflex coronary artery and the proximal 10 to 50 mm segment of the right coronary artery using a dedicated workstation (Aquarius iNtuition Edition version 4.4.13; TeraRecon Inc., Foster City, CA, USA), as previously described. Within the pre-identified segment of interest, the lumen as well as the inner and outer vessel wall border were tracked in an automated manner with additional manual optimization. Adipose tissue was defined as all voxels with attenuation between −190 HU and −30 HU. The PCATA was defined as the average CT attenuation in the factors associated with FFR. (Table 2) The multivariable analysis demonstrated that minimum lumen

CT-derived LV mass index and cardiac mass at risk. LV mass was indexed by body surface area (LV mass/BSA; LVMI). The % cardiac mass at risk was defined as the % ratio of the subtended cardiac mass at risk to the whole left ventricular myocardial mass. Details are described in Method 2 in the Supplemental Materials.

CMR image acquisition, coronary sinus flow and g-CFR measurement. CMR image acquisition was performed using a 1.5-Tesla scanner (Philips Achieva, Philips Medical Systems, Best, The Netherlands) with 32-channel cardiac coils. PC-CMR image acquisition and g-CFR quantification by absolute CSF measurement were performed as previously described. Briefly, the coronary sinus was identified in the atrioventricular groove using the basal slices of the short-axis stack. The plane for flow measurement by PC-CMR was positioned perpendicular to the CS at 1 to 2 cm from the ostium. PC-CMR of the CSF measurement was performed during maximal hyperemia and at rest. Maximal stable hyperemia was induced by intravenous adenosine (140 μg/kg per min through a central vein). The CSF quantitative analyses were performed in a blinded fashion by two expert investigators (Y. Kanaji and T Misawa), using proprietary software (Philips View Forum, Best, The Netherlands) (Fig. 2b). The resting CSF value was corrected using rate pressure products (RPP) as follows: rate pressure product = systolic blood pressure (mm Hg) × heart rate; corrected CSF = (CSF/RPP) × 10,000; and corrected CSF (ml/min per g) = corrected CSF/LVM (g). G-CFR was evaluated by CSF reserve, which was calculated as CSF during maximal hyperemia divided by resting CSF.

Statistical analysis. The patients were divided into two groups by the g-CFR value of 2.0, which are indicated to be associated with major cardiac adverse events. Clinical characteristics, CCTA-derived data, and CMR-derived variables were compared between these two groups. Statistical analyses were performed using SPSS version 25.0 (IBM Corporation, Armonk, NY, USA). Categorical data were expressed as numbers and percentages and compared by chi-square or Fisher’s exact tests, as appropriate. Continuous data were expressed as median (interquartile range [IQR]) and analyzed using the Mann–Whitney test and the variance for variables with non-normal distribution and normal distribution, respectively. Correlations between 2 variables were assessed using Pearson’s correlation analysis. Receiver operating characteristic curves were analyzed to assess the best cutoff values for predicting g-CFR < 2.0 (impaired g-CFR). Univariable and multivariable linear regression analyses were performed to determine predictive factors of FFR and g-CFR (stepwise-forward method; P < 0.05). Univariable and multivariable logistic regression analyses were also performed to predict g-CFR < 2.0. The Hosmer–Lemeshow statistic was applied to assess model calibration. The prediction model for g-CFR < 2.0 was constructed to determine the incremental discriminatory and reclassification performance of mean PCATA by using relative integrated discrimination improvement (IDI) and category-free net reclassification index (NRI). A 2-tailed value of P < 0.05 was considered statistically significant.

Results
Patient characteristics. The final analysis was performed by 131 patients in the present study (Fig. 1). The mean time interval between CCTA, CMR, and CAG was 45 days (28–52 days). The patients’ baseline characteristics in the two groups divided by the presence or absence of impaired g-CFR (< 2.0) are summarized in Table 1. Patient demographics, laboratory data including hs-CRP, angiographic stenosis severity, and lesion locations were comparable between the two groups except for creatinine level. The median FFR value was 0.75 and similar between the two groups. Although LVM and LVMI were both significantly different, subtended cardiac mass at risk by the target lesion was not significantly different between the groups. Significant mutual relationships among RCA, LAD, and LCx PCATA values were observed (Fig. 3), which was in line with the previous report. Mean PCATA of 3 major vessels and target vessel PCATA were higher in the group with impaired g-CFR compared with those without (P < 0.001, P = 0.003, respectively). Baseline CSF was significantly greater, and hyperemic CSF was significantly lower, resulting in significantly lower g-CFR values in the impaired g-CFR group. No significant association was observed between PCATA and hs-CRP (P = 0.30).

Determinants of FFR. The univariable and multiple linear regression analyses were performed to examine the factors associated with FFR. (Table 2) The multivariable analysis demonstrated that minimum lumen
diameter (MLD) (P < 0.001) and target vessel PCATA or the mean PCATA of 3 major vessels were independent predictors of FFR (P < 0.001, P < 0.001, respectively). There was a significant and robust relationship between the target vessel PCATA and the mean PCATA of 3 major vessels (R = 0.79, P < 0.001). The target vessel PCATA and the mean PCATA showed similar relationships with FFR, although the numerical difference in the strength of the relationship was observed. (Table 2).

**Determinants of g-CFR.** To examine the factors associated with g-CFR, we performed univariable and multiple linear regression analyses (Table 3). The univariable analysis identified that creatinine level, log (NT-
| Demographics | Total N=131 | With impaired g-CFR N=43 | Without impaired g-CFR N=88 | P value |
|--------------|------------|--------------------------|----------------------------|---------|
| Age, year    | 67 ± 10    | 68 ± 11                  | 67 ± 9                     | 0.83    |
| Male, n (%)  | 87 (66.4)  | 33 (76.7)                | 54 (61.4)                  | 0.08    |
| Body surface area, m² | 1.70 [1.56, 1.83] | 1.73 [1.60, 1.84] | 1.68 [1.55, 1.83] | 0.46    |

| Medical history, n (%) |          |                      |                            |         |
|------------------------|----------|----------------------|---------------------------|---------|
| Hypertension, n (%)    | 97 (74.0)| 31 (72.1)            | 66 (75.0)                 | 0.72    |
| Hyperlipidemia, n (%)  | 84 (64.1)| 26 (60.5)            | 58 (65.9)                 | 0.54    |
| Diabetes mellitus, n (%) | 55 (42.0) | 16 (37.2)          | 39 (44.3)                 | 0.44    |
| Current smoker, n (%)  | 35 (26.7)| 10 (23.3)            | 25 (28.4)                 | 0.53    |
| Family history, n (%)  | 20 (15.3)| 6 (14.0)             | 14 (15.9)                 | 0.77    |

| Prescription at admission, n (%) |        |                      |                            |         |
|----------------------------------|--------|----------------------|---------------------------|---------|
| Statin, n (%)                    | 114 (87.0)| 36 (83.7)          | 78 (88.6)                 | 0.43    |
| ACE-I or ARB, n (%)              | 75 (57.3)| 26 (60.5)            | 49 (57.7)                 | 0.60    |
| β-blocker, n (%)                 | 49 (37.4)| 20 (46.5)            | 29 (33.0)                 | 0.13    |
| Calcium antagonist, n (%)        | 62 (47.3)| 18 (41.9)            | 44 (50.0)                 | 0.38    |

| Coronary angiography |        |                      |                            |         |
|----------------------|--------|----------------------|---------------------------|---------|
| Target lesion location; RCA/LAD/LCx, n (%) | 20 (15.3)/103(78.6)/8(6.1) | 8(18.6)/33(76.7)/2(4.7) | 12 (13.6)/70(79.5)/6(6.8) | 0.70    |
| MLD, mm              | 0.85 [0.67, 1.26] | 0.82 [0.69, 1.30] | 0.85 [0.66, 1.19] | 0.55    |
| RD, mm               | 2.82 [2.43, 3.17] | 2.82 [2.34, 3.34] | 2.83 [2.49, 3.31] | 0.67    |
| DS, %                | 66.9 [56.8, 76.1] | 66.8 [57.0, 75.7] | 68.1 [56.8, 76.4] | 0.67    |

| Physiological data |        |                      |                            |         |
|--------------------|--------|----------------------|---------------------------|---------|
| FFR                 | 0.75 [0.61, 0.79] | 0.73 [0.63, 0.79] | 0.77 [0.58, 0.80] | 0.52    |
| FFR ≤ 0.75, n (%)   | 67 (51.1)| 24 (55.8)            | 43 (48.9)                 |         |

| Laboratory data |        |                      |                            |         |
|-----------------|--------|----------------------|---------------------------|---------|
| T-chol, mg/dl   | 181 [154, 208] | 181 [144, 213] | 180 [156, 205] | 0.98    |
| LDL-chol, mg/dl | 97 [78, 125]  | 95 [76, 130]        | 98 [79, 123]              | 0.85    |
| HDL-chol, mg/dl | 50 [44, 60]  | 48 [42, 54]         | 52 [44, 62]               | 0.10    |
| TG, mg/dl       | 125 [91, 182] | 135 [79, 176] | 125 [93, 197]              | 0.70    |

| CT data |        |                      |                            |         |
|---------|--------|----------------------|---------------------------|---------|
| Whole LV mass volume, cm³ | 136.5 [115.6, 160.3] | 141.4 [123.1, 171.2] | 133.0 [108.2, 157.5] | 0.011    |
| Whole LV mass volume, g   | 1440 [121.9, 169.1] | 1492 [129.8, 180.6] | 1403 [114.1, 166.2] | 0.011    |
| LV mass index by CT, g/m² | 83.4 [73.4, 93.3] | 85.9 [77.3, 97.3] | 82.4 [70.8, 91.7] | 0.015    |
| Area at risk mass volume, % | 32.7 [24.0, 39.0] | 30.7 [22.4, 38.5] | 33.0 [25.0, 39.0] | 0.60    |
| Area at risk mass volume, cm³ | 43.5 [31.1, 54.4] | 45.7 [31.4, 55.6] | 42.1 [30.1, 53.5] | 0.21    |
| Agatston score (target vessel) | 135.0 [25.1–385.7] | 214.6 [59.2–382.0] | 104.8 [18.3, 198.5] | 0.11    |
| Agatston score (total) | 314.0 [66.7–790.2] | 487.5 [118.5–914.3] | 180.2 [45.4–775.1] | 0.065    |

| CMR indices |        |                      |                            |         |
|-------------|--------|----------------------|---------------------------|---------|
| LV mass by CT, g/m² | 83.4 [73.4, 93.3] | 85.9 [77.3, 97.3] | 82.4 [70.8, 91.7] | 0.015    |
| Area at risk mass volume, % | 32.7 [24.0, 39.0] | 30.7 [22.4, 38.5] | 33.0 [25.0, 39.0] | 0.60    |
| Area at risk mass volume, cm³ | 43.5 [31.1, 54.4] | 45.7 [31.4, 55.6] | 42.1 [30.1, 53.5] | 0.21    |
| Agatston score (target vessel) | 135.0 [25.1–385.7] | 214.6 [59.2–382.0] | 104.8 [18.3, 198.5] | 0.11    |
| Agatston score (total) | 314.0 [66.7–790.2] | 487.5 [118.5–914.3] | 180.2 [45.4–775.1] | 0.065    |

| Mean |        |                      |                            |         |
|------|--------|----------------------|---------------------------|---------|
| PCATA | 73.8 [75.9–71.9] | 73.5 [70.2–76.0] | 73.0 [70.0–76.5] | <0.001  |
| PCATA | 73.8 [75.9–71.9] | 73.5 [70.2–76.0] | 73.0 [70.0–76.5] | <0.001  |
| PCATA | 73.8 [75.9–71.9] | 73.5 [70.2–76.0] | 73.0 [70.0–76.5] | <0.001  |
It has been recently reported that high-risk atherosclerotic plaque morphology was significantly associated with progression. The results of the present study indicated that PCATA was significantly associated with FFR. Improved when PCATA was added to the clinical risk model 1 + FFR for predicting g-CFR < 2.0, whereas FFR showed no significant additive predictive information to the clinical risk model 1 (Table 5).

Taqueti et al.8 in which g-CFR obtained by PET was associated with outcomes regardless of the angiographic markers of regional ischemia and systemic inflammation. Our findings are in line with the previous study by study exhibited a relatively weak albeit statistically significant association between pericoronary adipose tissue inflammation evaluated by CT attenuation in epicardial functional stenosis severity and g-CFR. This relationship was independent of FFR and hs-CRP, which were used as standard markers of regional ischemia and systemic inflammation. Our findings are in line with the previous study by Taqueti et al.5 in which g-CFR obtained by PET was associated with outcomes regardless of the angiographic

Table 1. Clinical characteristics of patients with and without impaired g-CFR (g-CSF < 2.0). ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; cTnl, cardiac troponin I; CT, computed tomography; CSF, coronary sinus flow; EDV, end diastolic volume; EF, ejection fraction; eGFR, estimated glomerular filtration rate; ESV, end systolic volume; g-CFR, global coronary flow reserve; HbA1c, glycated hemoglobin; HDL-cholesterol, high density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein; HU, Hounsfield units; LAD, left anterior descending coronary artery; LCx, left circumflex coronary artery; LDL-cholesterol, low density lipoprotein cholesterol; LVM, left ventricular mass; LVMi, left ventricular mass index; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PCATA, pericoronary adipose tissue attenuation; RCA, right coronary artery; TG, triglyceride; TIMI, thrombolysis in myocardial infarction.

Inflammatory and reclassification performance of PCATA. Clinical risk model 1 was constructed by using age, male sex, diabetes mellitus, creatinine, high sense troponin I, NT-proBNP, LVMi, target lesion in LAD, and area at risk of subtended cardiac mass volume. NRI and IDI indices were significantly improved when PCATA was added to the clinical risk model 1 + FFR for predicting g-CFR < 2.0, whereas FFR showed no significant additive predictive information to the clinical risk model 1 (Table 5).

Discussion

The important findings of the present study are as follows. In patients with CAD with a single de novo stenosis and preserved systolic function: (1) the mean PCATA was significantly associated with epicardial functional stenosis severity determined by FFR; (2) the mean PCATA was an independent predictor of reduced g-CFR. To the best of our knowledge, this is the first study to demonstrate the physiological significance of pericoronary inflammation evaluated by CT attenuation in epicardial coronary stenosis severity and g-CFR.

FFR and PCATA. Inflammation has been widely demonstrated to play a pivotal role in driving atherosclerotic progression. The results of the present study indicated that PCATA was significantly associated with FFR. It has been recently reported that high-risk atherosclerotic plaque morphology was significantly associated with FFR16. Perivascular inflammation drives the development and progression of coronary atherosclerosis5. PCATA, a surrogate marker of local inflammation, was demonstrated to be associated with coronary plaque instability and high-risk characteristics17. Our result is in line with these studies. Although current findings may provide an important insight into the association between perivascular inflammation and epicardial functional stenosis severity, other factors such as lesion morphology, plaque burden, plaque specific inflammation, local oxidative stress, and endothelial dysfunction might affect stenosis severity as previously reported18,19, further large population studies are required to test this hypothesis-generating finding.

G-CFR and PCATA. G-CFR has been demonstrated as a powerful predictor of worse outcomes independent of epicardial coronary stenosis severity1,20. However, pathophysiologic determinants of global CFR have not been fully elucidated. Our main hypothesis of the present study was to evaluate the physiological significance of PCATA in epicardial functional stenosis severity and g-CFR. Considering the complexity and difficulty of evaluating the association of epicardial functional stenosis with global flow by the limited population, we focused on the single de novo lesion with intermediate to severe stenosis in the present study, by excluding multivessel disease and including functionally significant and non-significant stenoses in the study population. The present study exhibited a relatively weak albeit statistically significant association between pericoronary adipose tissue inflammation and g-CFR. This relationship was independent of FFR and hs-CRP, which were used as standard markers of regional ischemia and systemic inflammation. Our findings are in line with the previous study by Taqueti et al.5 in which g-CFR obtained by PET was associated with outcomes regardless of the angiographic
severity of coronary artery disease, although our study could not evaluate outcomes. G-CFR is an integrated marker of coronary function, including epicardial coronary stenosis, diffuse atherosclerosis, and microvascular

Figure 3. Association of PCATA values between the three major epicardial coronary arteries. (a) RCA and LAD, (b) RCA and LCx, and (c) LAD and LCx.
Our results may suggest that patients with intermediate to severe epicardial coronary disease have a significant extent of diffuse disease and/or microvascular dysfunction, impacting on g-CFR independent of and over the regional ischemia in association with pericoronary inflammation. There is growing evidence that microvascular dysfunction is associated with increased inflammation and may precede or coexist with high-risk coronary atherosclerosis. In addition, it has also been demonstrated that endothelial dysfunction and coronary microvascular dysfunction could be affected by systemic inflammation. Our results further indicate the importance of the link between inflammation and microvascular dysfunction because both may share a similar characteristic that extends beyond coronary vascular territory, not confined to a target vessel territory, which is defined by FFR. Our findings suggest that not only epicardial lesion severity, but also other factors including microvascular function, endothelial function and vasodilatory ability may be linked with the extent of pericoronary inflammation in patients with coronary artery disease and preserved systolic function. This hypothesis is merely a speculative explanation of the mechanism linking local perivascular adipose tissue inflammation with g-CFR and our results showed no causal inference between perivascular inflammation and atherosclerosis.

The present study included only the patients with single-vessel disease. Assuming that the severity of diffuse atherosclerosis or microvascular disease in non-obstructive vessels might play an important role in the association between PCATA and reduced or preserved g-CFR in patients with CAD, further studies are needed to clarify if the sum of FFR values of three major coronary arteries significantly correlated with global CFR and/or PCATA. Global CFR represents not only the effect of epicardial stenosis but the integral of the coronary artery flow characteristics including diffuse non-obstructive disease and microvascular dysfunction. Considering the relatively weak albeit statistically significant association between PCATA and g-CFR, other factors such as renal impairment linking with oxidative stress and endothelial inflammation might play an important role in the reduction of g-CFR. Mechanistic insights of reduced global CFR may be multi-factorial and complex, thus further large sample size studies are needed to define the pathophysiological mechanisms and outcomes linking...

|                   | Univariable analysis |          |          |          |          | Multivariable analysis 1 |          |          | Multivariable analysis 2 |          |          |
|-------------------|---------------------|----------|----------|----------|----------|--------------------------|----------|----------|--------------------------|----------|----------|
|                   | β                   | 95% CI   | P value  | β        | 95% CI   | P value                  | β        | 95% CI   | P value                  | β        | 95% CI   |
| Age, year         | 0.002               | 0.000 to 0.004 | 0.10 | 0 | −0.001 to 0.003 | 0.43 | β | 0.001 | −0.001 to 0.003 | 0.47 |
| Male              | −0.053              | −0.100 to −0.005 | 0.03 | 0.023 | −0.020 to −0.065 | 0.29 | 0.031 | −0.012 to −0.007 | 0.68 |
| MLD, mm           | 0.163               | 0.121 to 0.205 | <0.001 | 0.165 | 0.124 to 0.206 | <0.001 | 0.168 | 0.129 to 0.207 | <0.001 |
| DS, %             | 0                   | −0.001 to 0.000 | 0.24 | 0 | −0.001 to 0.000 | 0.24 | 0 | −0.001 to 0.000 | 0.24 |
| Lesion length, mm | −0.001              | −0.004 to 0.002 | 0.61 | 0 | −0.002 to 0.001 | 0.83 | 0 | −0.019 to 0.038 | 0.33 |
| NT-proBNP, pg/ml  | 5.3 × 10⁻⁴          | 0.000 to 0.000 | 0.68 | 0 | −0.002 to 0.001 | 0.83 | 0 | −0.019 to 0.038 | 0.33 |
| cTnI at presentation, ng/l | 0 | −0.002 to 0.001 | 0.83 | 0 | −0.002 to 0.001 | 0.83 | 0 | −0.019 to 0.038 | 0.33 |
| hs-CRP, mg/dl     | 0.19                | −0.019 to 0.038 | 0.33 | 0 | −0.019 to 0.038 | 0.33 | 0 | −0.019 to 0.038 | 0.33 |
| Target lesion: LAD | 0.084               | 0.030 to 0.138 | 0.003 | 0.030 | −0.019 to 0.078 | 0.23 | 0.042 | −0.004 to 0.089 | 0.077 |
| IV mass index by CT, g/m² | −0.001              | −0.002 to 0.001 | 0.28 | 0 | −0.002 to 0.001 | 0.28 | 0 | −0.002 to 0.001 | 0.28 |
| Area at risk mass volume, g | −0.001              | −0.002 to 0.000 | 0.26 | 0 | −0.019 to 0.078 | 0.12 | 0 | −0.001 to 0.000 | 0.082 |
| Agatston score (Target vessel) | −2.1 × 10⁻³ | 0.000 to 0.000 | 0.43 | 0 | −0.002 to 0.000 | 0.62 | 0 | −0.002 to 0.000 | 0.62 |
| EE %              | 0.001               | −0.002 to 0.004 | 0.62 | 0 | −0.002 to 0.000 | 0.28 | 0 | −0.002 to 0.000 | 0.28 |
| Mean PCATA        | −0.007              | −0.010 to −0.003 | <0.001 | Not selected | −0.010 to −0.003 | <0.001 | Not selected | −0.010 to −0.003 | <0.001 |
| Highest PCATA     | −0.007              | −0.010 to −0.003 | <0.001 | Not selected | −0.010 to −0.003 | <0.001 | Not selected | −0.010 to −0.003 | <0.001 |
| Target vessel PCATA | −0.006              | −0.009 to −0.003 | <0.001 | −0.005 to −0.003 | <0.001 | Not selected | −0.005 to −0.003 | <0.001 |
| CSF at hyperemia, ml/min/g | 0.004               | −0.015 to 0.023 | 0.67 | 0 | −0.015 to 0.023 | 0.67 | 0 | −0.015 to 0.023 | 0.67 |
| Corrected g-CFR   | 0.009               | −0.012 to 0.031 | 0.39 | 0 | −0.012 to 0.031 | 0.39 | 0 | −0.012 to 0.031 | 0.39 |

Table 2. Univariate and multiple linear regression analysis for FFR.
with inflammation and g-CFR. Incremental prognostication by these variables over clinical risk factors should be also evaluated in the future studies.

**Clinical implications of PCATA.** Our results indicated that low-level local inflammation, which was not associated with hs-CRP, could be assessed by PCATA, and showed a significant association with both FFR and g-CFR. In contrast, FFR did not contribute to g-CFR values in CAD patients with single epicardial stenosis and preserved systolic function. Considering that global CFR has been established as an integrated marker of the...

Table 3. Univariate and multiple linear regression analysis for g-CFR.

| Variable                      | Univariable analysis | Multivariable analysis 1 | Multivariable analysis 2 |
|-------------------------------|----------------------|--------------------------|--------------------------|
|                               | β        | 95% CI          | P value     | β        | 95% CI          | P value     | β        | 95% CI          | P value     |
| Age, year                     | −0.006   | −0.026 to 0.013 | 0.54        |           |           |             |           |           |             |             |
| Male                          | −0.235   | −0.629 to 0.159 | 0.24        |           |           |             |           |           |             |             |
| HDL-cholesterol, mg/dl        | 0.003    | −0.013 to 0.020 | 0.69        |           |           |             |           |           |             |             |
| Creatinine, mg/dl             | −1.162   | −2.018 to −0.306 | 0.008  | −1.873   | −2.55      | 0.010  | −0.917   | −1.710 to −0.123 | 0.024 |
| cTnI at presentation, ng/l    | −0.009   | −0.022 to 0.004 | 0.18        |           |           |             |           |           |             |             |
| log (NT-proBNP), pg/ml        | −0.172   | −0.321 to −0.023 | 0.024  | −0.240   | −0.064     | 0.29  | −0.152   | 0.289 to −0.015 | 0.030 |
| CRP, mg/dl                    | 0.176    | −0.142 to 0.494 | 0.28        |           |           |             |           |           |             |             |
| FFR                           | 0.624    | −0.796 to 2.045 | 0.39        |           |           |             |           |           |             |             |
| Whole LV mass volume, g       | −0.009   | −0.014 to −0.004 | <0.001     |           |           |             |           |           |             |             |
| LV mass index by CT, g/m²     | −0.017   | −0.026 to −0.008 | <0.001     | −0.004   | −0.014 to 0.007 | 0.50   |           |             |             |
| Area at risk mass volume, g   | −0.010   | −0.018 to −0.002 | 0.019      | 0        | −0.001 to 0.008 | 0.85   |           |             |             |
| Mean PCATA                    | −0.061   | −0.090 to −0.032 | <0.001     | Not selected | −0.049   | −0.081 to 0.016 | 0.004   |           |             |             |
| Highest PCATA                 | −0.048   | −0.074 to −0.023 | <0.001     | Not selected | Not selected |             |           |             |             |
| Target vessel PCATA           | −0.040   | −0.065 to −0.014 | 0.002  | −0.019   | −0.047 to 0.008 | 0.17   | Not selected |             |             |
| EDV, ml                       | −0.012   | −0.020 to −0.005 | 0.001  | −0.016 to 0.001 | 0.004   | −0.008 | −0.015 to 0.000 | 0.041 |

Figure 4. A linear relationship between mean PCATA and g-CFR. There is a significant relationship between mean PCATA and g-CFR (R = 0.37, P < 0.001).
pathophysiological status of epicardial coronary stenosis, diffuse atherosclerosis, microvascular function, and myocardial tissue perfusion\(^2\), the disease monitoring and patient managements might be guided by the combined assessment of PCATA and g-CFR using CT and CMR that are widely available and accessible in the clinical practice, since the association between PCATA and g-CFR in this study is relatively weak. The present study, however, could evaluate no causal inference between PCATA and g-CFR. Recently, van Diemen et al. reported that RCA PCATA was a significant predictor of worse outcomes in CAD patients, independent of myocardial ischemia\(^2\)\(^6\). The authors evaluated regional hyperemic myocardial blood flow (MBF), and hyperemic MBF of each vessel did not correlate with vessel-specific PCATAs. In contrast, we analyzed the mean PCATA which may represent the net assessment of 3 vessel specific PCATA obtained from 3 major coronary arteries, indicating the status of inflammation of the whole heart pericoronary adipose tissue. Our results that the regional functional stenosis evaluated by FFR was not correlated with g-CFR were in line with their study, although our study had no outcome data. Given that no significant relationship was observed between FFR and g-CFR, these two crucial indices evaluate different pathophysiological abnormalities in CAD patients and might provide complementary prognostic information. Our result demonstrated that NT-pro BNP and serum creatinine level were the significant factors of impaired g-CFR. Coronary microvascular dysfunction has been proposed to be an important mechanism underlying the pathogenesis of heart failure, while previous study showed that comorbidities such as obesity, diabetes mellitus, chronic kidney disease led to systemic inflammation, coronary endothelial inflammation and microvascular dysfunction\(^7\). The results of this study suggest that pericoronary inflammation obtained by CCTA may provide the assessment of diverse pathophysiologic pathways responsible for the development of atherosclerosis in CAD and might help identify high-risk CAD patients for worse outcomes independent of regional functional stenosis. Furthermore, future therapeutic strategies directed towards reducing PCATA that

### Table 4. Univariate and multivariate logistic regression analysis for factors to predict impaired g-CFR (g-CFR < 2.0).

|                          | Univariable analysis | Multivariable analysis 1 | Multivariable analysis 2 |
|--------------------------|----------------------|---------------------------|---------------------------|
|                          | HR       | 95% CI        | P value | HR       | 95% CI        | P value | HR       | 95% CI        | P value |
| Age, year                | 1.004    | 0.967–1.043   | 0.83    |           |             |         |           |             |         |
| Male                     | 2.078    | 0.908–4.753   | 0.083   |           |             |         |           |             |         |
| HDL-chol, mg/dl          | 0.979    | 0.946–1.013   | 0.21    |           |             |         |           |             |         |
| Creatinine, mg/dl        | 11.182   | 1.190–105.102 | 0.035   | 10.614   | 1.036–108.771| 0.047   | 9.903    | 1.375–127.6 | 0.047   |
| cTnI at presentation, ng/l | 1.011    | 0.986–1.036   | 0.39    |           |             |         |           |             |         |
| log (NT-proBNP), pg/ml   | 1.270    | 0.942–1.712   | 0.12    |           |             |         |           |             |         |
| CRP, mg/dl               | 0.769    | 0.358–1.651   | 0.50    |           |             |         |           |             |         |
| FFR                      | 0.627    | 0.040–9.910   | 0.74    |           |             |         |           |             |         |
| FFR ≤ 0.75               | 1.322    | 0.635–2.751   | 0.46    |           |             |         |           |             |         |
| Whole LV mass volume, g  | 1.015    | 1.004–1.026   | 0.006   |           |             |         |           |             |         |
| LV mass index by CT, g/m² | 1.030    | 1.009–1.051   | 0.004   | 1.018    | 0.995–1.042 | 0.052   | 1.007    | 0.987–1.029 | 0.070   |
| Area at risk mass volume, g | 1.012    | 0.9955–1.030  | 0.16    |           |             |         |           |             |         |
| Mean PCATA               | 1.140    | 1.060–1.225   | <0.001  | 1.141    | 1.060–1.229 | 0.002   | Not selected | Not selected | Not selected |
| Highest PCATA            | 1.116    | 1.049–1.188   | 0.001   | Not selected | Not selected | Not selected | Not selected | Not selected | Not selected |
| Target vessel PCATA      | 1.096    | 1.034–1.161   | 0.002   | 1.095    | 1.032–1.161 | 0.003   | Not selected | Not selected | Not selected |
| EDV, ml                  | 1.020    | 1.004–1.036   | 0.016   | 1.011    | 0.993–1.029 | 0.10    | 1.011    | 0.994–1.030 | 0.19    |

### Table 5. Comparison of discriminant and reclassification ability of clinical models. To determine incremental discriminatory and reclassification capacities of mean PCATA for predicting g-CFR < 2.0 Clinical model 1: age, male sex, DM, creatinine, cTnI at presentation, log (NT-proBNP), LV mass index, target lesion: LAD, Area at risk.

| Prediction model | AUC (95% CI) | P value | IDI | P value | NRI | P value |
|------------------|--------------|---------|-----|---------|-----|---------|
| Clinical model 1 | 0.69 (0.60–0.78) | Reference | Reference |
| Clinical model 2: model1 + FFR | 0.69 (0.59–0.78) | 0.81 | 0.0013 | 0.66 | 0.0655 | 0.72 |
| Clinical model 3: model 2 + mean PCATA | 0.79 (0.70–0.87) | 0.015 | 0.0936 | <0.001 | 0.4604 | 0.003 |
| Clinical model 2: model1 + FFR | 0.69 (0.59–0.78) | Reference | Reference |
| Clinical model 3: model 2 + mean PCATA | 0.79 (0.70–0.87) | 0.015 | 0.0923 | <0.001 | 0.5307 | 0.003 |
represent the specific inflammatory status of the cardiovascular system may potentially provide a novel management option for improving prognosis.

**Study limitations**
The results of the present study should be interpreted with consideration for several significant limitations. First, this study included a relatively small number of patients from a single-center, which may not allow extensive subgroup analysis or more reliable multivariable analyses. Furthermore, this study was conducted on the limited population with single-vessel disease. The future studies including multi-vessel disease are crucial since multi-vessel CAD has been reported to be observed in 40–50% of stable coronary artery disease (CAD) patients and are correlated with worse clinical outcomes compared with single-vessel CAD in clinical practice. Second, this study provided no outcome data. Third, CMR perfusion imaging was not performed according to the protocol in the present study. CMR perfusion-defined ischemia might provide an important insight into the association between PCATA and regional CFR. Forth, currently, there is no widely available proprietary software that can automatically analyze PCATA. However, the software used in the present study is commercially available, and the CT hardware used was a single system that gives us the strength of the study. Furthermore, CT is currently an essential tool to risk-stratify patients with known and suspected coronary artery disease with worldwide availability. Forth, in this study, the use of statins was about 90%, but LDL levels were still suboptimal (median 97 mg/dl). Statins have been reported to provide a significant reduction of vascular inflammation. Although further high dose statins might have reduced PCATA, it is plausible that residual inflammation after lipid-lowering therapy was suggested from our results of PCATA, because no significant relationship between LDL levels and PCATA was observed and the non-negligible portion of patients with LDL levels lower than 70 mg/dl showed increased PCATA. In other words, targeting PCATA after lipid-lowering therapy may provide the opportunity to manage residual risk. Finally, our study is cross-sectional and merely hypothesis-generating; thus, it cannot discern the temporal relationship between pericoronary inflammation and reduced g-CFR. Further studies are needed to test our results.

**Conclusions**
The present study demonstrated the significant relationship between pericoronary inflammation represented by PCATA and g-CFR independent of epicardial stenosis severity evaluated by FFR in CAD patients with a single de novo lesion and preserved systolic function. PCATA might be able to monitor disease extent or test the impact of future therapeutic interventions. Further studies with larger sample sizes and outcome measures are warranted.

**Data availability**
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Received: 2 May 2021; Accepted: 26 August 2021
Published online: 24 September 2021

**References**
1. Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. *N. Engl. J. Med.* 352, 1685–1695. https://doi.org/10.1056/NEJMra043430 (2005).
2. Hansson, G. K., Libby, P. & Tabas, I. Inflammation and plaque vulnerability. *J. Intern. Med.* 278, 483–493. https://doi.org/10.1111/j.1460-619X.2010.03406 (2015).
3. Ross, R. Atherosclerosis is an inflammatory disease. *Am. Heart J.* 138, S419–S420. https://doi.org/10.1016/s0002-8703(99)70266-8 (1999).
4. Oikonomou, E. K. et al. Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): A post-hoc analysis of prospective outcome data. *Lancet* 392, 929–939. https://doi.org/10.1016/s0140-6736(18)31114-0 (2018).
5. Antonopoulos, A. S. et al. Detecting human coronary inflammation by imaging perivascular fat. *Sci. Transl. Med.* https://doi.org/10.1126/scitranslmed.aal2658 (2017).
6. Johnson, N. P. et al. Prognostic value of fractional flow reserve: Linking physiologic severity to clinical outcomes. *J. Am. Coll. Cardiol.* 64, 1641–1654. https://doi.org/10.1016/j.jacc.2014.07.973 (2014).
7. Murthy, V. L. et al. Effects of sex on coronary microvascular dysfunction and cardiac outcomes. *Circulation* 129, 2518–2527. https://doi.org/10.1161/CIRCULATIONAHA.113.008507 (2014).
8. Taqueti, V. R. et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. *Circulation* 131, 19–27. https://doi.org/10.1161/CIRCULATIONAHA.114.019359 (2015).
9. Ziad, M. C. et al. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. *J. Am. Coll. Cardiol.* 58, 740–748. https://doi.org/10.1016/j.jacc.2011.01.065 (2011).
10. Schweitzer, J. et al. Magnetic resonance-based assessment of global coronary flow and flow reserve and its relation to left ventricular functional parameters: A comparison with positron emission tomography. *Circulation* 101, 2696–2702. https://doi.org/10.1161/01.cir.101.23.2696 (2000).
11. Koskenuo, J. W. et al. Global myocardial blood flow and global flow reserve measurements by MRI and PET are comparable. *J. Magn. Reson. Imaging* 13, 361–366 (2001).
12. Budoff, M. J. et al. Assessment of coronary artery disease by cardiac computed tomography: A scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. *Circulation* 114, 1761–1791. https://doi.org/10.1161/CIRCULATIONAHA.106.178458 (2006).
13. Abbara, S. et al. SCCT guidelines for the performance and acquisition of coronary computed tomographic angiography: A report of the society of Cardiovascular Computed Tomography Guidelines Committee: Endorsed by the North American Society for Cardiovascular Imaging (NASCI). *J. Cardiovasc. Comput. Tomogr.* 10, 435–449. https://doi.org/10.1016/j.jcct.2016.10.002 (2016).
Author contributions

Y.K., T.S., M.H., T.M., T.N., Y.Y., K.N., H.U., H.H., M.H., M.Y., R.H. and E.U. made effort to enroll the patients. Y.K., T.S., M.H., T.M., T.N., Y.Y., K.N., H.U., H.H., M.H., M.Y., R.H. and E.U. and T.K. analyzed and interpreted the patient data. Y.K., T.S., M.H., T.M., T.N., Y.Y., K.N., H.U., H.H., M.H., M.Y., R.H. and E.U. and T.K. approved the final manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-97849-5.

Correspondence and requests for materials should be addressed to T.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021